low - Clinical-stage biotechs are largely insulated from GDP fluctuations as R&D spending is pre-committed and not tied to consumer demand. However, severe recessions can impact ability to raise capital and affect acquisition appetite from larger pharma companies.

Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (barzolvolimab revenues unlikely before 2028-2029). Higher rates also increase opportunity cost of holding non-income-producing growth stocks vs. fixed income. Conversely, the company's substantial cash balance benefits from higher yields on short-term investments, partially offsetting burn rate. Rate environment also affects M&A activity as acquirers face higher financing costs.

growth - High-risk, high-reward profile attracts biotech specialists, venture-style investors, and momentum traders betting on binary clinical catalysts. Not suitable for value or income investors given negative cash flow and no dividends. Institutional holders typically specialized healthcare funds with expertise evaluating clinical data and regulatory pathways.